Regulation of osmolality for cancer treatment
Disseminated metastasis is associated with a poor prognosis, and its management in the peritoneal or pleural cavity is crucial in the treatment of cancer. Recent studies show that ion and water transporters play important roles in fundamental cellular functions, including the regulation of cell volume that would be involved in the cancer process. Here, we review the evidence for hypotonic treatments of cancer and evaluate the potential of the cellular physiological approach in clinical management. The regulation of extracellular osmolality is a promising method, with several studies demonstrating the cytocidal effects of hypotonic solution on cancer cells. Peritoneal lavage with distilled water (DW) during surgery is reported to improve the survival rate of patients with spontaneously ruptured hepatocellular carcinoma. The in vitro studies included in this review also indicate the cytocidal effects of hypotonic shock on esophageal, gastric, colonic, pancreatic, and liver cancer cells with several unique methods and apparatuses, such as a differential interference contrast microscope connected to a digital video camera, a high-resolution flow cytometer and re-incubation analysis. The in vivo studies demonstrate the safeness of a peritoneal injection of DW into mice and indicate that the development of dissemination nodules can be prevented by the pre-incubation of cancer cells with DW or the peritoneal injection of DW. We also demonstrate that the blockade of Cl− channels/transporters enhances the cytocidal effects of hypotonic shock by inhibiting regulatory volume decrease in various cancer cells. A deeper understanding of molecular mechanisms may lead to the discovery of these cellular physiological approaches as a novel therapeutic strategy for disseminated metastasis.
KeywordsDisseminated metastasis Cancer Hypotonic treatment Regulatory volume decrease Cl− channel
The authors would like to thank Dr. Michihiro Kudou for technical assistance with the experiments.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 7.Takahara N, Isayama H, Nakai Y, Sasaki T, Ishigami H, Yamashita H, Yamaguchi H, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Mohri D, Kawakubo K, Kogure H, Yamamoto N, Sasahira N, Hirano K, Ijichi H, Tateishi K, Tada M, Kitayama J, Watanabe T, Koike K (2014) Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. J Gastrointest Cancer 45:307–311CrossRefPubMedGoogle Scholar
- 11.Miyazaki H, Marunaka Y (2015) The molecular mechanism of intracellular Cl− function in gastric cancer invasion and metastasis by regulating expression of cell adhesion molecules. J Physiol Sci 65[Suppl 1]:72Google Scholar
- 13.Marunaka Y (2016) Cl− and H+ as mediators of biofunction and biodysfunction in health and disease. J Physiol Sci 66[Suppl 1]:4Google Scholar
- 14.Miyazaki H, Ue T, Tanaka S, Nakayama Y, Marunaka Y (2016) The molecular mechanism of intracellular Cl− in cancer progression by regulating Src kinase signal cascades. J Physiol Sci 66[Suppl 1]:159Google Scholar
- 20.Ichinose Y, Hara N, Ohta M, Asoh H, Yano T, Maeda K, Yagawa K (1993) Hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in patients with lung cancer. In vitro experiments and preliminary clinical results. J Thorac Cardiovasc Surg 10:1041–1046Google Scholar
- 24.Nako Y, Shiozaki A, Ichikawa D, Komatsu S, Konishi H, Iitaka D, Ishii H, Ikoma H, Kubota T, Fujiwara H, Okamoto K, Ochiai T, Nakahari T, Marunaka Y, Otsuji E (2012) Enhancement of the cytocidal effects of hypotonic solution using a chloride channel blocker in pancreatic cancer cells. Pancreatology 12:440–448CrossRefPubMedGoogle Scholar
- 25.Takemoto K, Shiozaki A, Ichikawa D, Komatsu S, Konishi H, Nako Y, Murayama Y, Kuriu Y, Nakanishi M, Fujiwara H, Okamoto K, Sakakura C, Nakahari T, Marunaka Y, Otuji E (2015) Evaluation of the efficacy of peritoneal lavage with distilled water in colorectal cancer surgery: in vitro and in vivo study. J Gastroenterol 50:287–297CrossRefPubMedGoogle Scholar
- 26.Kudou M, Shiozaki A, Kosuga T, Ichikawa D, Konishi H, Morimura R, Komatsu S, Ikoma H, Fujiwara H, Okamoto K, Hosogi S, Nakahari T, Marunaka Y, Otsuji E (2016) Inhibition of regulatory volume decrease enhances the cytocidal effect of hypotonic shock in hepatocellular carcinoma. J Cancer 7:1524–1533CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Shiozaki A, Ichikawa D, Takemoto K, Nako Y, Nakashima S, Shimizu H, Kitagawa M, Kosuga T, Konishi H, Komatsu S, Fujiwara H, Okamoto K, Marunaka Y, Otsuji E (2014) Efficacy of a hypotonic treatment for peritoneal dissemination from gastric cancer cells: an in vivo evaluation. Biomed Res Int 2014:707089PubMedPubMedCentralGoogle Scholar
- 39.Ichinose Y, Tsuchiya R, Koike T, Yasumitsu T, Nakamura K, Tada H, Yoshimura H, Mitsudomi T, Nakagawa K, Yokoi K, Kato H (2002) A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: the incidence of carcinomatous pleuritis after surgical intervention. J Thorac Cardiovasc Surg 123:695–699CrossRefPubMedGoogle Scholar
- 42.Seto T, Ushijima S, Yamamoto H, Ito K, Araki J, Inoue Y, Semba H, Ichinose Y, Thoracic Oncology Group (2006) Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial. Br J Cancer 95:717–721CrossRefPubMedPubMedCentralGoogle Scholar